Klotho: the longevity protein that just entered human trials

TL;DR

• The mouse data are dramatic - knocking out the KL gene in 1997 produced accelerated ageing; overexpressing it extended lifespan.
• The human data are observational - higher circulating α-klotho tracks with better kidney, vascular and cognitive outcomes, which is not the same as causing them.
• The kidney is the confounder - it makes most of the circulating protein, so klotho may be an excellent marker of renal health rather than a lever on it.
• The genetics are suggestive, not decisive - one copy of KL-VS associates with better outcomes, two copies with worse, so more signalling is not simply better.
• The trial running now is a Phase 1b - AKL003, 21 healthy adults, randomised 2:1, primary objective safety and tolerability, at a single site in Honduras.
• Nothing purchasable raises klotho to a level shown to benefit anyone - the assay has no established reference range and no validated clinical action attached.
• The commercial layer is now bigger than the evidence layer - an annual conference, corporate joint ventures and press-released company data, with no randomised human trial reporting a clinical benefit.
• Quality-of-life goals are a separate conversation. None of the options in the new section is a klotho intervention, but energy, recovery and libido are legitimate goals in their own right, and the section lists what people discuss with a physician, with the evidence and status for each.

Educational content, not medical advice. Klotho therapeutics are investigational and not approved anywhere. No doses or protocols appear. Nothing here is a recommendation to seek, purchase or participate in any treatment.

Updated October 2026: the Second Annual Klotho Conference has now taken place (Miami, 18-19 September 2026); the conference section is updated with what was actually presented (a preclinical encapsulated-cell talk, no animal or human results released), and the AKL003 trial status is re-checked (no results reported as of 20 October 2026).

Updated September 2026: adds a dated section on the commercial and conference layer forming around klotho (the Second Annual Klotho Conference and the encapsulated-cell α-klotho data a company has announced it will present there), framed as commercial and educational activity that has run ahead of the human evidence base, not as a result.

---

Klotho has spent about twenty-five years as the longevity field's most tantalising loose end. It is named after one of the Greek Fates - the one who spins the thread of life - which tells you something about how the discovery was received. The animal data have always been dramatic enough to justify the name. The human data have never quite caught up, and the gap between the two is where most of what you have read about klotho lives.

This page sets out what the protein actually is, what is and is not established in people, whether measuring your own levels tells you anything useful, and what the trial currently running can realistically deliver.

What klotho actually is

Klotho was identified in 1997, by accident. Researchers disrupted a gene in mice and produced animals that aged with unusual speed - shortened lifespan, vascular calcification, bone loss, skin atrophy, cognitive decline - a syndrome resembling accelerated human ageing across several systems at once. The disrupted gene was named KL, and its product klotho.

The finding that made the field pay attention came later: mice engineered to overexpress klotho lived longer than controls. A single gene whose loss accelerates ageing and whose excess extends life is rare, and it moved klotho immediately into a small category of genuinely interesting longevity targets.

α-klotho vs β-klotho

The word "klotho" on its own is ambiguous, and the ambiguity matters because it is the source of a lot of confused reading.

α-klotho is the one the longevity conversation is about. It exists in two forms: a membrane-bound version acting as a co-receptor for fibroblast growth factor 23 (FGF23) in phosphate and vitamin D regulation, and a soluble version, cleaved and released into blood and cerebrospinal fluid, which appears to act as a circulating signalling factor in its own right. Soluble α-klotho is what "klotho levels" almost always refers to.

β-klotho is a different protein, a co-receptor for FGF21 and FGF19, involved in metabolic and bile-acid signalling. It is scientifically interesting and largely irrelevant to the longevity claims. When a source says "klotho" without a prefix, it nearly always means α-klotho - but not always, and the difference is not cosmetic.

Why the kidney matters here

α-klotho is expressed most heavily in the kidney, particularly in the distal tubules, with meaningful expression also in the choroid plexus of the brain and the parathyroid gland. That distribution has a consequence that shapes the entire human literature: the kidney is the dominant source of circulating klotho, so anything that damages kidney function lowers klotho levels.

Chronic kidney disease is therefore a state of klotho deficiency, and it is also a state associated with vascular calcification, accelerated cardiovascular ageing, cognitive decline and shortened lifespan. That overlap is the single biggest confounder in the field, and we return to it below, because it explains why so many klotho associations are real and so few are interpretable.

The evidence in animals, and why it does not transfer cleanly

The mouse work is strong and reasonably consistent. Klotho-deficient mice show the accelerated-ageing syndrome; klotho-overexpressing mice show extended lifespan; and in several models, restoring or supplementing klotho improves cognitive, vascular or renal endpoints.

Three reasons for caution before carrying that across.

The deficiency model is extreme. Klotho-knockout mice are not models of normal ageing with a slightly lower klotho level. They are models of near-total loss of a protein central to phosphate handling, and much of their phenotype is downstream of severe mineral dysregulation. Showing that catastrophic deficiency causes a disease-like state does not show that ordinary variation in klotho drives ordinary ageing.

Lifespan extension in mice is a low bar to clear and a poor predictor. A long list of interventions extend mouse lifespan and have not translated - the animals are short-lived, genetically homogeneous, housed in conditions that remove most real-world mortality risks, and their dominant causes of death differ from ours.

Delivery is unsolved. Klotho is a large protein. Getting a therapeutically relevant amount of it into the right tissues in a human - particularly across the blood-brain barrier, where several of the more exciting cognitive findings point - is a genuinely hard pharmacological problem, and it is the problem the current trials exist to work on.

What human klotho levels are associated with

In people, higher circulating α-klotho has been associated with lower all-cause mortality, better kidney function, less vascular calcification and arterial stiffness, better cognitive performance and lower frailty. The associations are reasonably consistent across cohorts, which is worth something.

Observational vs causal

It is worth being precise about what those studies can support, because this is where most klotho coverage overreaches.

These are observational findings. They establish that people with higher klotho tend to be healthier. They do not establish that klotho is doing the work. Given that the kidney produces most circulating klotho, and that kidney function declines with age and with essentially every major cardiometabolic disease, there is an obvious alternative reading: klotho may be an excellent marker of renal and vascular health rather than a lever on it. A biomarker that faithfully reports how well your kidneys are doing would produce exactly the association pattern we observe, without klotho itself being causal at all.

Statistical adjustment for kidney function helps but does not settle it, because the adjustment is imperfect and the confounding is structural rather than incidental.

The genetic data

Genetics offers a partial way around the confounding, and it is the strongest human evidence klotho has.

KL-VS is a common variant of the klotho gene. Carrying one copy (heterozygosity) has been associated in multiple cohorts with modestly better cognitive performance, lower cardiovascular risk and in some analyses greater longevity. Because genotype is fixed at conception and is not altered by your later kidney function, this design is much less vulnerable to reverse causation than the observational work.

Two things keep it from being decisive. First, the effect is not linear: carrying two copies has been associated with worse outcomes in several analyses, which is biologically interesting and clinically awkward, and it means "more klotho signalling is better" is not a claim the genetics support. Second, the findings have been inconsistent across populations, and the cognitive effects in particular have not replicated uniformly.

So the genetic data raise the plausibility that klotho is on the causal path. They do not establish that raising it in an adult produces benefit.

Can you measure your own klotho?

Increasingly, yes - and the more useful question is what you would do with the number.

What a serum α-klotho assay does and doesn't tell you

Serum soluble α-klotho can be measured by ELISA, and the assay is used routinely in research. Several direct-to-consumer longevity panels have added it. The technical caveats are substantial: inter-assay variability is high, results are not reliably comparable between platforms, and there is no established reference range defining a "good" or "target" level for a healthy adult. Levels also decline with age, vary with kidney function, and fluctuate.

What that adds up to: a single klotho value has no validated clinical interpretation. There is no threshold at which a clinician is expected to act, and no intervention with demonstrated benefit to act with. A low reading in someone with unrecognised kidney impairment might reasonably prompt a look at renal function - but standard renal markers would find that more directly and more cheaply.

Where it sits against epigenetic clocks

If you are already testing biological age, the honest comparison is unflattering in both directions. Epigenetic clocks have far more validation work behind them and still carry real interpretive problems - a point we make at length in why biological age tests disagree. Klotho has less. It is a single analyte with known assay instability and no consensus range, whereas a clock is a composite with published training and test performance.

Against that, klotho is at least a specific, mechanistically grounded quantity rather than an aggregate, which is arguably an advantage for research. For personal decision-making today it remains, as with most of this category, a measurement in search of an action. Functional markers - grip strength, gait speed, VO₂ max - still outperform every molecular measure on the one criterion that matters most, which is that you can actually change them and the change means something.

What is actually in trials right now

The reason klotho re-entered the conversation in 2026 is a specific trial, and it is worth describing accurately because the description has drifted.

The Phase 1b mRNA study

Klothea Bio announced in February 2026 the launch of a randomised, double-blind, placebo-controlled Phase 1b study of AKL003, an investigational alpha-klotho mRNA therapeutic. The study enrols 21 healthy adults aged 25 to 75, randomised two-to-one to active treatment or saline placebo, with repeat intravenous administration. Its primary objective is safety and tolerability. It also collects a set of exploratory biomarkers associated with healthspan.

Two features of the study belong in any accurate summary. It is being conducted at a single site outside the United States - the GARM Clinic in Prospera, Roatán, Honduras, a special jurisdiction with its own regulatory framework. That is not by itself a criticism of the science, but it means the trial is not running under FDA oversight, and readers comparing it to trials that are should know that. And AKL003 is investigational: not approved in any jurisdiction, not available by prescription, and not purchasable.

A second klotho cluster is also visible, and it is commercial rather than clinical. It is described in its own section below, because what it signals is a field forming rather than anything having been shown.

Why a 21-person Phase 1b cannot answer a lifespan question

This is the part worth internalising, because it generalises far beyond klotho.

A Phase 1b study asks: is this tolerated, and what does it do to short-term biology? With twenty-one participants split across two arms, it has the statistical power to detect frequent or severe adverse events and essentially nothing else. It cannot detect uncommon harms. It cannot establish efficacy on any clinical endpoint. And it categorically cannot address lifespan, because lifespan in healthy adults aged 25 to 75 is measured in decades and this study is measured in weeks.

The exploratory biomarkers are the part most likely to generate headlines, and they are the part that carries the least weight. An exploratory endpoint in a Phase 1b is a hypothesis-generating observation: it is not powered, it is not the trial's primary question, and in a study this size a difference between arms can easily arise by chance. If AKL003 moves a healthspan biomarker, that is a reason to run a larger trial. It is not a result about ageing.

A useful rule: the question a trial was designed to answer is the only question its result speaks to. Everything else in the report is a reason to design the next study.

The commercial and conference layer, as of October 2026

The other visible development in klotho's 2026 is not a trial result. It is infrastructure.

The Second Annual Klotho Conference took place in Miami on 18-19 September 2026, convened around the future of klotho-based therapies. Avaí Bio, Inc. (OTCQB: AVAI) and its joint-venture partner Austrianova, through their venture Klothonova, had announced by press release that they would present data from an investigational α-klotho anti-ageing approach: production of α-klotho from genetically modified, encapsulated cells, intended to restore circulating α-klotho on a sustained basis. At the conference, Austrianova's chief technology officer gave a 20-minute talk on the approach and an update on development work. The companies' own follow-up release (24 September 2026) states that the programme remains preclinical, and it reports no animal or human efficacy results; the milestones it lists are manufacturing steps, such as a GMP master cell bank and its safety testing.

Read that for precisely what it is. A company presenting its own preclinical work at a conference, and describing it by press release, is not peer-reviewed human trial evidence. Nothing has been published, nothing has been through external review, and until data enter the public record in a form others can examine there is nothing in it to assess, favourably or unfavourably. Some of the promotion around the programme has also appeared as paid investor advertising, which is a further reason to read it as marketing rather than evidence. The approach is investigational: not approved in any jurisdiction, not available by prescription, not purchasable. The ticker appears above only so the entity can be identified unambiguously; nothing here is a comment on any company as an investment, and this page takes no position on one.

What the conference showed is worth naming separately, because it is the honest read on klotho in late 2026. The field now has an annual meeting, corporate joint ventures, delivery platforms under active development, a direct-to-consumer assay and a supplement market attached to its name. What it does not have is a randomised trial in humans reporting a clinical benefit. The commercial and scientific-conference apparatus around klotho is now substantially larger than the human evidence base underneath it - and the first is far quicker and cheaper to build than the second.

That mismatch is not evidence of bad faith. New fields look like this early, and conferences are how a research community organises itself. But it does mean the volume of activity around a target tells you nothing about whether the target works, and a reader who encounters klotho through a press release, a conference agenda or a product page is encountering the infrastructure rather than the evidence. The two are easy to mistake for one another precisely because the infrastructure arrives first.

Things sold as "klotho boosters" and what the evidence says

Because klotho is a protein made in your own tissues rather than a compound you can take, a supplement market has grown up around things claimed to raise your own production.

The honest position on all of it: there is no intervention with demonstrated ability to raise human klotho to a level shown to produce a clinical benefit. Several things have been associated with higher klotho in humans - regular aerobic exercise most consistently - but the association is modest, and it faces the same interpretive problem as everything else here, namely that exercise improves renal and vascular health, which raises klotho, which may be a consequence rather than a mechanism. Various compounds have been reported to raise klotho expression in cell or animal models; none has human outcome data.

Three specific things to be sceptical of:

• Oral "klotho" products. Klotho is a large protein; ingesting one generally results in its digestion. A product claiming to deliver klotho orally is making a pharmacological claim that requires evidence it does not have.
• Klotho-boosting claims attached to a supplement that already exists. Where a compound is already on the market and a klotho mechanism has been attached to it afterwards, the mechanism is usually marketing rather than the reason the product exists.
• The trial being cited as validation. A Phase 1b of an mRNA therapeutic says nothing whatsoever about a capsule, and its appearance in supplement marketing is a borrowed-credibility move.

The unglamorous version is the one with evidence behind it: the things that protect kidney and vascular function over decades - blood pressure control, glycaemic control, not smoking, sustained aerobic fitness - are also the things most plausibly associated with maintaining klotho. That is not a klotho protocol. It is general medicine, and it is what the klotho literature actually supports.

How klotho compares to other longevity targets

The pattern across the row is the same one, which is why it is worth laying out: in every case the animal biology is genuinely compelling, the human interventional record is thin, and the commercial offer has run well ahead of both. More detail in the evidence on senolytics and does NAD⁺ decline with age.

Quality-of-life goals alongside longevity: options to discuss with a physician

Readers interested in klotho are often just as interested in how they feel now: energy, recovery, sleep, libido. None of the products below is a klotho intervention. None has been shown to raise klotho in humans, and none should be read as a response to a klotho test result. They are listed because they are quality-of-life options people often discuss with a physician alongside an interest in longevity, and the evidence and status for each are stated plainly. Vivre Labs offers access, and we recommend beginning with baseline bloodwork (what to test); given everything above about the kidney, standard renal markers belong in that baseline anyway.

Energy

• MOTS-c is a peptide encoded in mitochondrial DNA, discussed for energy and metabolic health. Evidence: animal and cell studies; there is no completed interventional human trial. Status: investigational, not FDA-approved. An FDA advisory committee recommended it for the 503A compounding list in July 2026; that vote is advisory, and it has not been added.

Recovery, and a note on the name KLOW

• GLOW is a protocol combining BPC-157, TB-500 and GHK-Cu, aimed at recovery and skin. Evidence: overwhelmingly animal studies; in humans, one small uncontrolled chart review of BPC-157 for knee pain, with subjective outcomes only and no control group. Status: all three components are investigational in injectable form.
• KLOW is GLOW plus KPV, a short peptide fragment of alpha-MSH studied for inflammation, mostly in cell and animal models of gut inflammation. Despite the name, KLOW has nothing to do with klotho. KPV is investigational and not FDA-approved. KLOW has no product page of its own; the differences are set out in GLOW vs KLOW.

Longevity claims

• Epithalon (also spelled epitalon) is the peptide most often marketed with longevity claims. Evidence: mostly small Russian studies and animal work; no independent randomised trial has shown a lifespan or healthspan benefit in humans. Status: investigational, not FDA-approved; recommended by the FDA advisory committee for the 503A list in July 2026, but not added. More in Khavinson peptides. Like everything else in this section, it is not a klotho intervention.

Libido

• PT-141 (bremelanotide) is FDA-approved, as Vyleesi since 2019, only for acquired generalised hypoactive sexual desire disorder in premenopausal women. Any other use, including in men or after menopause, is off-label. Known side effects include nausea, flushing and a transient rise in blood pressure, which is one reason it needs a physician. See PT-141 (bremelanotide).
• Kisspeptin-10 is a fragment of a natural hormone that sits upstream of the reproductive axis. Evidence: small, short human studies of hormone release and of brain responses to sexual cues; no approved product. Status: investigational, not FDA-approved. Background in kisspeptin.

If klotho itself is the interest, the position from the rest of this page stands: there is nothing to take for it, and the evidence-backed route is protecting kidney and vascular health.

Frequently asked questions

Is klotho a peptide I can obtain? No. Klotho is a large protein produced by your own tissues, not a compound with a supply route. The only klotho-directed agent in human testing is an investigational mRNA therapeutic in a Phase 1b safety study, which is not available outside that trial. Anything sold as klotho should be treated as making a claim it cannot support.

Should I get my klotho level tested? There is currently no validated clinical use for the result. There is no established reference range, assay results vary substantially between platforms, and there is no intervention with demonstrated benefit that a result would guide. If the underlying concern is kidney or vascular health, standard renal and cardiovascular markers answer that question better and are interpretable by any clinician.

Does exercise raise klotho? Regular aerobic exercise is the intervention most consistently associated with higher circulating klotho in human studies. Whether that reflects klotho responding to better renal and vascular function, or klotho contributing to it, is unresolved. Either way, the recommendation does not change, and it does not depend on klotho being the mechanism.

If the KL-VS variant is protective, does that prove klotho works? It is the strongest human evidence available, and it is still not proof. Carrying one copy is associated with better outcomes in several cohorts; carrying two has been associated with worse outcomes, so the relationship is not a simple dose-response. And a genetic variant present from conception tells you about lifelong exposure, not about what happens if you raise klotho in an adult - which is the question a therapeutic has to answer.

What would change the picture? A larger randomised trial with a clinical or well-validated surrogate endpoint, in a population where klotho is plausibly limiting, reporting a benefit that survives adjustment for kidney function. Nothing short of that moves klotho from interesting biology to actionable. The current study is a necessary step toward that trial, not a substitute for it.

---

Related reading

• Epigenetic clocks - the most developed biological-age measures, and their limits
• What biological age tests measure - the gap between a number and an action
• Why biological age tests disagree - when two tests give you two ages
• Functional markers of biological age - the measures you can actually move

Part of Testing & Biological Age.

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore NAD⁺.

Educational content, not medical advice. Klotho therapeutics are investigational and not approved in any jurisdiction; none is available outside a clinical trial. No doses or dosing schedules appear anywhere on this page; compounds and protocols named in the quality-of-life section are linked for information, not prescribed. Claims for the Malaysian market are subject to MAB requirements. Company announcements and conference presentations described here are not peer-reviewed evidence, and no company is named as, or recommended as, an investment. Position stated as of 15 September 2026.

References

• Kuro-o M, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997. · Kurosu H, et al. Suppression of aging in mice by the hormone Klotho. Science. 2005. (overexpression, lifespan extension)
• α-klotho expression concentrated in renal distal tubule, choroid plexus and parathyroid; kidney is the dominant source of circulating soluble α-klotho - the basis of the marker-versus-mechanism confounding discussed above.
• KL-VS variant: heterozygosity associated with better cognitive and cardiovascular outcomes in several cohorts; homozygosity associated with worse outcomes in several analyses; replication inconsistent across populations.
• Serum soluble α-klotho ELISA: high inter-assay variability, no established reference range for healthy adults, no validated clinical decision threshold.
• Klothea Bio, AKL003: randomised, double-blind, placebo-controlled Phase 1b announced 19 February 2026; 21 healthy adults aged 25–75; 2:1 active-to-placebo; repeat intravenous administration; primary objective safety and tolerability, with exploratory healthspan biomarkers; single site, GARM Clinic, Prospera, Roatán, Honduras. Investigational; not approved in any jurisdiction. BioSpace
• Second Annual Klotho Conference, Miami, 18-19 September 2026. Avaí Bio, Inc. (OTCQB: AVAI) and joint-venture partner Austrianova (JV: Klothonova): 20-minute conference talk by Austrianova's co-founder and CTO on an encapsulated-cell approach to sustained α-klotho production; company release, 24 September 2026 (GlobeNewswire), states the programme remains preclinical and reports no animal or human efficacy data. Company press release and conference presentation; not peer-reviewed, and no published result is available to assess as of 20 October 2026. Ticker given for identification only; no investment implication.